

RESEARCH MONOGRAPH . COMPOUND PROFILE

Beta-Lapachone

A naturally derived 1,2-naphthoquinone from the lapacho tree, bioactivated selectively by NAD(P)H:quinone oxidoreductase 1 to induce tumor-specific programmed necrosis through futile redox cycling, massive reactive oxygen species generation, DNA damage, PARP1 hyperactivation, and catastrophic NAD⁺/ATP depletion.

DOCUMENT	KDC-MN-1487
ISSUED	2026-05-13
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	NQ01-bioactivatable ortho-naphthoquinone with selective tumor cytotoxicity through futile redox cycling and PARP1 hyperactivation

RESEARCH USE ONLY

ABSTRACT

Beta-lapachone is a naturally occurring ortho-naphthoquinone originally isolated from the heartwood of *Tabebuia avellanedae* (pau d'arco, lapacho) and synthesized from the prenylated naphthoquinone lapachol by acid-catalyzed cyclization. The compound is the canonical substrate of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2), a two-electron reductase that is overexpressed 5- to 100-fold in the majority of solid human cancers, including non-small cell lung, pancreatic ductal adenocarcinoma, breast, prostate, and head and neck squamous cell carcinomas, relative to matched normal tissue. NQO1-mediated two-electron reduction of beta-lapachone produces an unstable hydroquinone that spontaneously autoxidizes back to the parent quinone in a futile redox cycle consuming approximately 60 moles of NAD(P)H per mole of drug over a 2-hour exposure window. This cycle generates massive superoxide and hydrogen peroxide fluxes within the tumor cell, producing extensive oxidative DNA damage (predominantly single-strand breaks and oxidized bases) that triggers hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in the presence of elevated nuclear calcium. PARP1 hyperactivation consumes the cellular NAD⁺ pool into branched poly(ADP-ribose) polymers, producing catastrophic NAD⁺ and ATP depletion, mu-calpain activation, apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus, and programmed necrosis that is mechanistically distinct from classical apoptosis and independent of caspase activation, p53 status, and Bcl-2 family protein expression. The NQO1 dependence of the cytotoxic mechanism confers tumor selectivity: NQO1-negative cells

(including most normal tissues) are resistant to beta-lapachone at pharmacologically achievable concentrations, and dicoumarol (an NQO1 inhibitor) completely abrogates cytotoxicity in NQO1-positive cancer cell lines. Beta-lapachone was advanced into clinical development as ARQ 501 (an intravenous hydroxypropyl-beta-cyclodextrin inclusion complex) by ArQule, Inc. and subsequently as ARQ 761 (an improved intravenous formulation) by the University of Texas Southwestern Medical Center. Phase I trials in patients with advanced solid tumors established a maximum tolerated dose of 390 mg/m² as a 2-hour intravenous infusion every other week, with dose-limiting toxicities of hemolytic anemia and methemoglobinemia attributable to off-target redox cycling interaction with cytochrome b5 reductase in erythrocytes. A Phase II trial of ARQ 501 in combination with gemcitabine in treatment-naïve unresectable pancreatic adenocarcinoma demonstrated disease stabilization but did not produce objective tumor responses sufficient for registration. A separate clinical derivative, MB12066, was developed for metabolic syndrome indications and completed first-in-human pharmacokinetic and tolerability studies at oral doses of 10 to 400 mg. Beyond anticancer applications, beta-lapachone exhibits anti-inflammatory activity through suppression of NF-kappaB-driven cytokine expression in activated macrophages and microglia, anti-obesity effects through stimulation of energy expenditure and white adipose tissue browning via NQO1-dependent NADH oxidation, and antimicrobial activity against *Trypanosoma cruzi* and *Mycobacterium tuberculosis*. This monograph reviews the chemistry, synthesis, and natural product origin of beta-lapachone; the NQO1-dependent futile redox cycling mechanism in molecular detail; the comprehensive pharmacokinetic record including formulation challenges; the preclinical and clinical

evidence base across oncology, metabolic, and inflammatory indications; the reconstitution, sourcing, and handling considerations for laboratory work; and a comparative assessment of five NQO1-targeted or naphthoquinone-class compounds against beta-lapachone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any therapeutic indication. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Common name: Beta-lapachone.

Systematic synonyms: 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione. Also referred to in older literature as beta-lapachona, and in some commercial catalogs as ARQ 501 (the cyclodextrin-complexed intravenous formulation developed by ArQule, Inc.).

Development codes: ARQ 501 (ArQule; hydroxypropyl-beta-cyclodextrin inclusion complex for intravenous administration), ARQ 761 (University of Texas Southwestern Medical Center; improved intravenous formulation), MB12066 (oral beta-lapachone derivative for metabolic indications).

Chemical Abstracts Service registry number: 4707-32-8.

International Union of Pure and Applied Chemistry name: 2,2-dimethyl-3,4-dihydro-2H-naphtho[1,2-b]pyran-5,6-dione.

PubChem Compound Identifier: CID 3885.

1.2 Structural class and chemistry

Beta-lapachone is an ortho-naphthoquinone (1,2-naphthoquinone) bearing a 2,2-dimethylpyran ring fused to the 1,2-positions of the naphthalene ring system. It is one of three naturally occurring isomers of lapachone: alpha-lapachone (a para-naphthoquinone, or 1,4-naphthoquinone, with a linear pyran fusion), beta-lapachone (the ortho-naphthoquinone with an angular pyran fusion), and the minor isomer dehydro-alpha-lapachone. Beta-lapachone is the pharmacologically most active of the three isomers with respect to NQO1-mediated redox cycling and is the minority product in the natural plant extract; it is therefore principally obtained by chemical synthesis from lapachol rather than by direct extraction [1, 2].

Molecular formula: C₁₅H₁₄O₃.

Exact mass: 242.0943 g/mol (monoisotopic).

Molecular weight: 242.27 g/mol.

Physical properties: Yellow crystalline solid. Melting point approximately 154 to 156 degrees Celsius. Poorly soluble in water (approximately 0.038 mg/mL at ambient temperature). Soluble in dimethyl sulfoxide, ethanol, and chloroform. The low aqueous solubility has been a principal formulation challenge throughout the clinical development of the compound and has driven the use of cyclodextrin inclusion complexes, polymeric micelles, and other solubilization strategies [3, 4].

Stereochemistry: Beta-lapachone does not contain a stereocenter in its parent structure. The compound is achiral and is supplied as a single molecular species. Investigators should confirm identity by nuclear magnetic resonance spectroscopy and mass spectrometry against a reference standard.

1.3 Synthesis

Beta-lapachone is synthesized from lapachol, a prenylated 1,4-naphthoquinone that is readily extracted in multigram quantities from the heartwood and inner bark of several *Tabebuia* species (principally *Tabebuia avellanedae*, also known as *Handroanthus impetiginosus* in revised taxonomy). The classical synthesis proceeds by treatment of lapachol with concentrated sulfuric acid, which induces cyclization of the prenyl side chain onto the adjacent quinone carbonyl oxygen to form the angular pyran ring system of beta-lapachone [1, 5]. The reaction proceeds at room temperature or with mild heating and produces beta-lapachone in moderate to good yield (typically 40 to 70 percent) after recrystallization from ethanol or ethyl acetate. The alpha-lapachone isomer (the linear pyran fusion product) is the kinetic product under some conditions and can be separated chromatographically.

An alternative synthesis from lomatiol (extracted from seeds of *Lomatia* species) has been reported but is less commonly used owing to the limited availability of the starting material [2]. Total synthesis from simple aromatic precursors is feasible but is not economically competitive with semi-synthesis from natural lapachol.

Industrial and research-grade production follows the lapachol semi-synthesis route. The product is purified by column chromatography or recrystallization and characterized by proton and carbon-13 nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. Purity of commercial research-grade material is typically greater than 98 percent by HPLC.

2. Abstract

Beta-lapachone is a naturally derived ortho-naphthoquinone that functions as a bioactivatable prodrug selectively lethal to cancer cells expressing elevated levels of NAD(P)H:quinone oxidoreductase 1 (NQO1). The compound undergoes NQO1-mediated two-electron reduction to an unstable hydroquinone that spontaneously reverts to the parent quinone through autoxidation, establishing a futile redox cycle that generates massive intracellular superoxide and hydrogen peroxide fluxes, consumes cellular NAD(P)H stores, produces extensive oxidative DNA damage, and triggers PARP1 hyperactivation with consequent catastrophic NAD⁺ and ATP depletion and programmed necrosis [6, 7, 8].

The NQO1 selectivity of the mechanism is the central pharmacological feature. NQO1 is a phase II detoxification enzyme that is paradoxically overexpressed 5- to 100-fold in the majority of solid human tumors relative to adjacent normal tissue, including pancreatic ductal adenocarcinoma (approximately 90 percent NQO1-positive), non-small cell lung cancer (approximately 80 percent), breast cancer (approximately 60 to 80 percent), prostate cancer (approximately 60 percent), and head and neck squamous cell carcinoma [9, 10]. This tumor-selective overexpression confers the therapeutic window: NQO1-positive cancer cells die uniformly at beta-lapachone concentrations of 2 to 6 micromolar with 30 to 60 minutes of exposure, while NQO1-negative cells and most normal tissues are resistant at these concentrations. The cytotoxicity is independent of p53 status, Bcl-2 family protein expression, oncogene driver mutations (KRAS, EGFR, HER2), and caspase activation, conferring activity against drug-resistant and apoptosis-deficient tumor populations [6, 7].

Beta-lapachone was advanced into clinical trials as ARQ 501 (Phase I and Phase II in advanced solid tumors and pancreatic cancer) and ARQ 761 (Phase I in advanced solid tumors). The maximum tolerated dose of ARQ 761 was established at 390 mg/m² intravenously every other week. Dose-limiting toxicities were hemolytic anemia and methemoglobinemia, attributable to off-target redox cycling with erythrocyte cytochrome b5 reductase rather than to the intended NQO1-mediated mechanism [11, 12]. Disease stabilization was observed in NQO1-positive tumors, but objective response rates were insufficient for single-agent registration. Current

preclinical research focuses on combination strategies with PARP inhibitors, ionizing radiation, and DNA base excision repair inhibitors that synergize with the NQO1-mediated DNA damage mechanism [13, 14].

Beyond oncology, beta-lapachone exhibits NQO1-dependent metabolic effects through stimulation of cytosolic NADH oxidation, producing increased energy expenditure, white adipose tissue browning, and amelioration of diet-induced obesity and metabolic syndrome in rodent models [15]. Anti-inflammatory effects through NF-kappaB suppression in activated macrophages and microglia, and antimicrobial activity against *Trypanosoma cruzi* and *Mycobacterium tuberculosis*, have been characterized in preclinical systems [16, 17]. A clinical derivative, MB12066, completed first-in-human pharmacokinetic trials for metabolic syndrome at oral doses of 10 to 400 mg with acceptable tolerability [18].

This monograph documents chemistry, synthesis, NQO1-dependent redox cycling pharmacology, comprehensive pharmacokinetics, the clinical evidence base across oncology and metabolic indications, sourcing and quality verification considerations, reconstitution and handling, stack-interaction implications, adverse-event signal, and a structured comparative assessment of five NQO1-targeted or naphthoquinone-class candidates against beta-lapachone.

3. Discovery and Development History

3.1 Origin and ethnobotanical context

Beta-lapachone derives from the inner bark of trees in the genus *Tabebuia* (Bignoniaceae), principally *Tabebuia avellanedae* (pau d'arco, lapacho, taheebo), a large deciduous tree native to the tropical and subtropical forests of Central and South America. Indigenous Amazonian communities used bark preparations of *Tabebuia* species for the treatment of fevers, malaria, syphilis, cutaneous infections, gastrointestinal disorders, and inflammatory conditions for centuries before European contact [1, 19]. The first scientific isolation of a bioactive naphthoquinone from *Tabebuia* bark was reported by Emanuele Paterno in 1882, who characterized lapachol (the prenylated 1,4-naphthoquinone precursor to beta-lapachone) from *Tabebuia avellanedae* [1].

3.2 Early pharmacological interest

During the 1960s, lapachol attracted considerable attention in Brazil and Argentina following reports of antitumor activity in popular media and early preclinical studies. The United States National Cancer Institute (NCI) included *Tabebuia* extracts in its systematic screening of plant-derived anticancer compounds beginning in the late 1960s. Lapachol entered NCI-sponsored Phase I clinical trials for cancer in the early 1970s but was discontinued due to anticoagulant toxicity (vitamin K antagonism) at doses required for antitumor activity [20]. Beta-lapachone, the angular isomer of lapachone produced by acid-catalyzed cyclization of lapachol, was subsequently identified as a more potent antitumor agent without the anticoagulant liability of the parent compound.

3.3 Identification of the NQO1 bioactivation mechanism

The modern pharmacology of beta-lapachone was established in the late 1990s and early 2000s through the work of David Boothman and colleagues at Case Western Reserve University (subsequently University of Texas Southwestern Medical Center). The seminal contribution was the demonstration that beta-lapachone cytotoxicity in cancer cells is entirely dependent on NQO1 expression: dicoumarol (an

NQO1 inhibitor) completely abrogates the cytotoxicity, and NQO1-negative cell lines are resistant at pharmacologically achievable concentrations [6, 21]. The Boothman laboratory subsequently characterized the full mechanistic cascade from NQO1-mediated futile redox cycling through reactive oxygen species generation, DNA damage, PARP1 hyperactivation, NAD⁺/ATP depletion, mu-calpain activation, AIF nuclear translocation, and caspase-independent programmed necrosis [7, 8].

3.4 Clinical development

ArQule, Inc. (Woburn, Massachusetts) acquired clinical development rights to beta-lapachone and formulated the compound as ARQ 501, a hydroxypropyl-beta-cyclodextrin (HPbeta-CD) inclusion complex for intravenous administration. ARQ 501 entered Phase I clinical trials in patients with advanced solid tumors in 2005 (NCT00099190) and Phase II trials in combination with gemcitabine for treatment-naïve unresectable pancreatic adenocarcinoma [11, 22]. The ARQ 501 development was limited by hemolytic toxicity attributable in part to the HPbeta-CD vehicle at the concentrations required for drug solubilization.

The Boothman laboratory at UT Southwestern subsequently developed ARQ 761, an improved intravenous formulation, and conducted a Phase I dose-escalation study in 42 patients with refractory advanced solid tumors (NCT01502800), published in 2018. ARQ 761 established a maximum tolerated dose of 390 mg/m² as a 2-hour infusion every other week, with dose-limiting toxicities of anemia and transient hypoxia reflecting methemoglobinemia [12]. Modest single-agent activity was observed, appearing associated with tumor NQO1 expression. A Phase I/Ib trial of ARQ 761 in combination with gemcitabine/nab-paclitaxel for advanced pancreatic cancer was subsequently initiated [23].

3.5 Metabolic syndrome derivative

Independently, MB12066, an oral beta-lapachone derivative, was developed for metabolic syndrome indications based on the NQO1-dependent stimulation of cytosolic NADH oxidation and energy expenditure observed in preclinical models. MB12066 completed first-in-human combined single and multiple ascending dose Phase I trials demonstrating acceptable pharmacokinetics and tolerability at doses of 10 to 400 mg in healthy subjects [18].

3.6 Current status

As of monograph preparation, beta-lapachone is not approved by any regulatory authority for any therapeutic indication. The compound remains in active preclinical and early clinical investigation, with the principal focus on NQO1-targeted combination strategies in pancreatic cancer and non-small cell lung cancer. Research-grade beta-lapachone is commercially available from multiple suppliers. The clinical derivatives ARQ 501 and ARQ 761 are not commercially available outside of clinical trial settings.

4. Mechanism of Action

Beta-lapachone is a multi-mechanism compound whose principal cytotoxic activity is entirely dependent on the intracellular enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1). Additional pharmacological activities, including topoisomerase inhibition, anti-inflammatory signaling, and metabolic modulation, contribute to the broader biological profile.

4.1 NQO1-mediated futile redox cycling

NQO1 (DT-diaphorase, EC 1.6.5.2) is a cytosolic flavoprotein that catalyzes obligate two-electron reduction of quinones to hydroquinones using NAD(P)H as the electron donor. Under normal physiological conditions, this two-electron reduction is a detoxification mechanism: the hydroquinone products are stable, readily conjugated by phase II enzymes (glucuronosyltransferases, sulfotransferases), and excreted. For most quinone substrates, NQO1 reduction therefore diverts the substrate away from one-electron reduction pathways (mediated by cytochrome P450 reductase and other one-electron reductases) that produce reactive semiquinone radicals [9, 10].

Beta-lapachone subverts this protective mechanism. NQO1 reduces beta-lapachone to the corresponding hydroquinone with high catalytic efficiency (kcat/Km approximately $2.7 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$), but the resulting hydroquinone is thermodynamically unstable and spontaneously autoxidizes back to the parent quinone with a half-life of approximately 20 to 30 seconds under physiological conditions [6, 7]. This establishes a futile redox cycle in which each molecule of beta-lapachone is repeatedly reduced by NQO1 and reoxidized by molecular oxygen, consuming approximately 60 moles of NAD(P)H and generating approximately 120 moles of superoxide per mole of drug over a 2-hour exposure. The superoxide is converted by superoxide dismutase to hydrogen peroxide, which constitutes the proximal cytotoxic species [6].

The futile cycle is distinctive in two respects. First, it is catalytic rather than stoichiometric: each molecule of beta-lapachone cycles repeatedly, amplifying the oxidative stress far beyond what a single-turnover drug could produce. Second, it is NQO1-dependent: cells lacking NQO1 expression (including most normal tissues,

which express NQO1 at low basal levels) do not generate the hydroquinone at sufficient rates to sustain the cycle, and dicoumarol (a competitive NQO1 inhibitor) completely blocks the cytotoxicity [6, 21].

4.2 DNA damage and PARP1 hyperactivation

The massive hydrogen peroxide flux generated by the futile redox cycle produces extensive oxidative DNA damage, predominantly 8-oxoguanine lesions, single-strand breaks, and abasic sites. This damage is recognized by the base excision repair (BER) pathway, and the initial step of BER processing (incision by apurinic/apyrimidinic endonuclease 1, APE1) produces additional single-strand breaks. The cumulative burden of single-strand breaks exceeds the capacity of normal PARP1-mediated repair and, in the presence of elevated intracellular calcium (itself a consequence of oxidative stress-mediated calcium release from endoplasmic reticulum stores), triggers PARP1 hyperactivation [7, 8].

Hyperactivated PARP1 catalyzes the massive synthesis of branched poly(ADP-ribose) (PAR) polymers from NAD⁺, consuming the cellular NAD⁺ pool within minutes. Because NAD⁺ is required for glycolysis (at the glyceraldehyde-3-phosphate dehydrogenase step) and for mitochondrial oxidative phosphorylation (as NADH), NAD⁺ depletion produces concurrent collapse of both glycolytic and oxidative ATP production. The resulting bioenergetic crisis triggers mu-calpain activation, which cleaves and releases apoptosis-inducing factor (AIF) from the inner mitochondrial membrane. AIF translocates to the nucleus, where it induces large-scale chromatin condensation and DNA fragmentation characteristic of programmed necrosis [7, 8].

4.3 Independence from classical apoptosis

The beta-lapachone cell death pathway is mechanistically distinct from classical caspase-dependent apoptosis. Cell death proceeds normally in the presence of pan-caspase inhibitors (zVAD-fmk), in cells overexpressing Bcl-2 or Bcl-xL, in p53-null cells, and in cells with homozygous BAX deletion [6, 7]. The independence from these canonical apoptosis regulators is a significant pharmacological advantage, as many advanced solid tumors harbor loss-of-function mutations in p53, overexpression of anti-apoptotic Bcl-2 family proteins, and other apoptosis-resistance mechanisms that compromise conventional cytotoxic chemotherapy.

4.4 Topoisomerase inhibition

Early characterization of beta-lapachone identified inhibition of DNA topoisomerase I as a contributing mechanism, with the compound stabilizing topoisomerase I-DNA cleavable complexes and inhibiting the religation step of the topoisomerase catalytic cycle [24]. Subsequent work established that the topoisomerase I inhibition occurs at concentrations (10 to 50 micromolar) substantially above those required for NQO1-mediated cytotoxicity (2 to 6 micromolar in NQO1-positive cells) and is therefore unlikely to contribute materially to the antitumor activity at pharmacologically achievable plasma concentrations. The topoisomerase I inhibition is nevertheless detectable in biochemical assays and may contribute to cytotoxicity in NQO1-negative cells at high concentrations.

4.5 Anti-inflammatory mechanisms

Beta-lapachone suppresses NF-kappaB-dependent transcription of proinflammatory cytokines (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) in lipopolysaccharide-activated macrophages and in activated microglia [16]. The mechanism involves inhibition of IkappaB kinase (IKK) phosphorylation and consequent stabilization of IkappaB-alpha, preventing nuclear translocation of the NF-kappaB p65/p50 heterodimer. Additionally, beta-lapachone suppresses matrix metalloproteinase expression (MMP-2, MMP-3, MMP-9) in activated microglia and modulates neuroinflammatory signaling pathways relevant to neurodegeneration [16]. The anti-inflammatory activity is observed at low-micromolar concentrations and is at least partially NQO1-dependent, suggesting that modulation of the cellular NAD⁺/NADH ratio contributes to the anti-inflammatory signaling.

4.6 Metabolic effects

Beta-lapachone stimulates NQO1-dependent oxidation of cytosolic NADH, effectively increasing the NAD⁺/NADH ratio and stimulating NAD⁺-dependent metabolic enzymes including the sirtuins (SIRT1, SIRT3) and AMP-activated protein kinase (AMPK) [15]. In high-fat diet-fed mice, beta-lapachone administration increased energy expenditure, stimulated browning of white adipose tissue through downregulation of miR-382 expression, and ameliorated obesity, glucose intolerance, dyslipidemia, and hepatic steatosis. These metabolic effects are the pharmacological basis for the MB12066 clinical derivative program in metabolic syndrome [15, 18].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and oral bioavailability

Beta-lapachone has poor oral bioavailability, measured at approximately 15.5 percent in rats, attributable to its extremely low aqueous solubility (0.038 mg/mL) and extensive first-pass metabolism in the liver and intestinal tract [3, 25]. The compound is rapidly absorbed from the gastrointestinal tract but undergoes substantial presystemic metabolism; considerable degradation is observed in liver, small intestine, and large intestine homogenates, while the compound is relatively stable in plasma [25].

Multiple formulation strategies have been investigated to improve oral bioavailability. Hydroxypropyl-beta-cyclodextrin (HPbeta-CD) inclusion complexes increase aqueous solubility to approximately 16 mg/mL (a 420-fold improvement) and improve oral bioavailability in preclinical models [4]. Crystalline solid dispersions have achieved oral bioavailability of approximately 32 percent in dogs, substantially higher than cocrystal (approximately 5 percent) or amorphous solid dispersion (approximately 1 percent) formulations of the same compound [26]. Polymeric micelle formulations, liposomal encapsulation, and nanoparticle delivery systems have been explored principally for parenteral administration in oncology applications [27].

5.2 Distribution

Beta-lapachone has a moderate to large volume of distribution in preclinical species, reflecting tissue partitioning. Plasma protein binding has not been extensively characterized in published literature but is estimated to be moderate based on the compound's lipophilicity (calculated LogP approximately 2.5). The compound distributes to solid tumors, liver, kidney, and lung in biodistribution studies. Tumor accumulation is enhanced by nanoparticle and polymeric micelle formulations that exploit enhanced permeability and retention in solid tumors [27].

5.3 Metabolism

Beta-lapachone undergoes extensive hepatic metabolism. The primary metabolic pathway is reduction of the quinone to the hydroquinone (mediated by NQO1 in tissues with high NQO1 expression, and by other reductases in the liver), followed by glucuronidation and sulfation of the hydroquinone. The compound is also metabolized by cytochrome P450 enzymes (principally CYP3A4) through hydroxylation and ring-opening pathways. The isomerization of beta-lapachone to alpha-lapachone has been investigated as a potential metabolic pathway *in vivo*; studies suggest that this isomerization is minimal in the human body under physiological conditions [28].

The extensive first-pass metabolism and rapid systemic clearance have been principal pharmacokinetic liabilities for the clinical development of the compound. The plasma elimination half-life in rats after intravenous administration is approximately 20 to 40 minutes, reflecting rapid hepatic clearance [25].

5.4 Elimination

Elimination is predominantly hepatic (metabolic clearance) rather than renal. Glucuronidated and sulfated metabolites are excreted in both urine and bile. Unchanged beta-lapachone in urine accounts for a negligible fraction of the administered dose.

5.5 Routes of administration

The principal route of administration in clinical trials has been intravenous infusion. ARQ 501 was administered as a 1-hour intravenous infusion of the HPbeta-CD inclusion complex. ARQ 761 was administered as a 2-hour intravenous infusion at doses of 195 to 450 mg/m² on weekly, every-other-week, or 2-of-3-week schedules [12]. The oral route has been used for MB12066 in metabolic syndrome trials at doses of 10 to 400 mg [18]. Preclinical routes include intraperitoneal, intravenous, and oral gavage in rodent models.

5.6 Special populations

Pharmacokinetic data in special populations (renal impairment, hepatic impairment, pediatric, geriatric) are limited to preclinical extrapolation. No human pharmacokinetic studies in special populations have been published. NQO1 polymorphism (NQO12, *a C609T missense variant producing a P187S substitution that is rapidly degraded by the proteasome*) is present at high frequency in certain populations (*approximately 22 percent homozygous NQO12/2 in East Asian populations, approximately 4 percent in European-ancestry populations*) and is a principal determinant of beta-lapachone efficacy rather than pharmacokinetics: NQO12/*2 homozygous tumors lack functional NQO1 protein and are resistant to beta-lapachone [9, 10].

6. Preclinical Pharmacology

6.1 In vitro antitumor activity

Beta-lapachone has been tested for cytotoxicity against more than 300 NQO1-positive cancer cell lines representing non-small cell lung cancer, pancreatic ductal adenocarcinoma, breast cancer, prostate cancer, and head and neck squamous cell carcinoma [6, 7]. NQO1-positive cancer cells die uniformly at beta-lapachone concentrations of 2 to 6 micromolar with a minimum exposure time of 30 to 60 minutes. Cell death proceeds through the NQO1-dependent programmed necrosis pathway regardless of oncogene driver status (KRAS, EGFR, HER2, BRAF), tumor suppressor status (p53, Rb, PTEN), and apoptosis regulator expression (Bcl-2, Bcl-xL, BAX). Dicoumarol (10 to 50 micromolar) completely abrogates the cytotoxicity, confirming NQO1 dependence.

6.2 In vivo antitumor activity

In subcutaneous and orthotopic xenograft models of NQO1-positive pancreatic cancer (MiaPaCa-2, CFPAC-1), beta-lapachone formulated in HPbeta-CD or in polymeric micelles produces extensive reductions in tumor burden, dramatic tumor growth delays, and extended survival at intravenous doses of 15 to 25 mg/kg administered 3 to 5 times per week [9, 21]. In orthotopic non-small cell lung cancer xenografts, similar efficacy has been demonstrated. Antitumor activity is absent in NQO1-negative xenograft models, confirming in vivo NQO1 selectivity.

6.3 Combination strategies

Several combination strategies exploit the NQO1-mediated DNA damage mechanism. Combination with PARP inhibitors (olaparib, talazoparib) produces synergistic tumor-selective DNA damage and apoptosis in NQO1-positive pancreatic and lung cancer xenografts: beta-lapachone generates the DNA damage substrate, and the PARP inhibitor prevents repair, converting sublethal single-strand breaks into lethal double-strand breaks [13]. Combination with ionizing radiation similarly produces synergistic NQO1-dependent tumor cell killing through enhancement of radiation-induced DNA damage [14]. Combination with gemcitabine produces additive

to synergistic effects in pancreatic cancer models through metabolic modulation of the nucleotide pool [23]. Inhibition of PCNA (proliferating cell nuclear antigen) enhances beta-lapachone cytotoxicity by augmenting oxidative stress-induced DNA damage and prolonging survival in Lewis lung carcinoma xenografts [29].

6.4 Anti-inflammatory and anti-infective preclinical activity

Beta-lapachone suppresses lipopolysaccharide-induced inflammatory cytokine production in RAW 264.7 macrophages and in BV-2 microglia at concentrations of 1 to 10 micromolar, with suppression of NF-kappaB nuclear translocation and downstream gene expression [16]. In rodent models of collagen-induced arthritis, beta-lapachone administration reduces joint inflammation and cartilage destruction. Antimicrobial activity against *Trypanosoma cruzi* (the causative agent of Chagas disease) has been characterized at low-micromolar concentrations, with the mechanism involving generation of oxidative stress in the parasite [17]. Activity against *Mycobacterium tuberculosis* has been reported in vitro.

6.5 Metabolic preclinical activity

In high-fat diet-fed C57BL/6 mice, beta-lapachone at oral doses of 50 to 100 mg/kg/day for 8 to 12 weeks prevents weight gain, increases energy expenditure, improves glucose tolerance, reduces serum lipids, and stimulates browning of white adipose tissue through NQO1-dependent NADH oxidation and downregulation of miR-382 [15]. NQO1 knockout mice are resistant to these metabolic effects, confirming the NQO1 dependence of the metabolic mechanism. The metabolic effects are the preclinical basis for the MB12066 clinical derivative program.

7. Clinical Evidence Base

7.1 Phase I: ARQ 501

ARQ 501 (beta-lapachone in HPbeta-CD) entered Phase I clinical trials in 2005 in patients with advanced refractory solid tumors (NCT00099190). The trial established tolerability at intravenous doses administered as a 1-hour infusion. Dose-limiting toxicity was hemolytic anemia, attributed in part to the HPbeta-CD vehicle at the high concentrations required for beta-lapachone solubilization [11]. The hemolytic liability was a principal factor driving reformulation to ARQ 761.

7.2 Phase II: ARQ 501 plus gemcitabine in pancreatic cancer

A Phase II study of ARQ 501 in combination with gemcitabine was conducted in adult patients with treatment-naïve, unresectable pancreatic adenocarcinoma [22]. The combination was tolerable, and disease stabilization was observed. However, objective response rates (partial or complete responses by RECIST criteria) were insufficient for registration as a single combination. The study contributed to the understanding of NQO1 expression as a potential predictive biomarker for beta-lapachone efficacy in pancreatic cancer.

7.3 Phase I: ARQ 761

The definitive Phase I study of the improved formulation ARQ 761 was conducted at UT Southwestern and published by Gerber et al. (2018) in the British Journal of Cancer [12]. A 3+3 dose-escalation design evaluated three schedules (weekly, every other week, 2-of-3 weeks) in 42 patients with refractory advanced solid tumors (median of 4 prior lines of therapy).

The maximum tolerated dose was 390 mg/m² as a 2-hour intravenous infusion every other week. The most common treatment-related adverse events were anemia (79 percent), fatigue (45 percent), hypoxia reflecting methemoglobinemia (33 percent), nausea (17 percent), and vomiting (17 percent). Grade 3 hypoxia (tran-

sient, reflecting methemoglobinemia) occurred in 26 percent of patients. The methemoglobinemia was attributed to off-target redox cycling interaction of beta-lapachone with cytochrome b5 reductase 1 (CYB5R1) in erythrocytes [12].

Pharmacodynamic analysis demonstrated that antitumor activity appeared associated with tumor NQO1 expression level, supporting NQO1 as a predictive biomarker. Disease stabilization was observed in several patients; the single-agent activity was characterized as modest.

7.4 Phase I/Ib: ARQ 761 plus gemcitabine/nab-paclitaxel

A Phase I/Ib multi-center trial of ARQ 761 in combination with gemcitabine/nab-paclitaxel was initiated in patients with advanced pancreatic cancer [23]. This trial represents the current clinical frontier for beta-lapachone in oncology, leveraging the rationale that beta-lapachone-mediated metabolic modulation (NAD⁺ depletion, glycolytic flux disruption) synergizes with gemcitabine-mediated nucleotide synthesis inhibition and nab-paclitaxel-mediated mitotic arrest.

7.5 MB12066: metabolic syndrome

MB12066, an oral beta-lapachone derivative, completed two first-in-human Phase I trials in healthy Korean subjects [18]. A combined single ascending dose (10 to 400 mg) and multiple ascending dose (100 and 200 mg for 7 days) design demonstrated acceptable pharmacokinetics and tolerability. No serious adverse events were reported at any dose level studied. The plasma half-life of MB12066 was substantially longer than that of beta-lapachone itself, consistent with structural modifications designed to improve oral bioavailability and metabolic stability. The compound was advanced for evaluation in metabolic syndrome indications based on the pre-clinical NQO1-dependent metabolic effects.

8. Sourcing and Quality Verification

Beta-lapachone is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, Selleckchem, MedChemExpress, Tocris, Santa Cruz Biotechnology, others) at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as the free base (yellow crystalline powder). Pricing is moderate, typically in the range of \$30 to \$150 per 100 milligrams of research-grade material at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (expected $[M+H]^+$ at m/z 243.10)
- Proton nuclear magnetic resonance spectroscopy (characteristic pyran ring methyl singlet at approximately δ 1.45 to 1.50 ppm, aromatic protons in the δ 7.5 to 8.1 ppm region)
- Differential scanning calorimetry or melting point determination (expected 154 to 156 degrees Celsius)
- Karl Fischer or loss-on-drying analysis for residual water content

Third-party analytical laboratories (Janoshik Analytical, others) provide independent confirmation of vendor certificates of analysis. The research-grade beta-lapachone market is well established; the compound is a commodity research chemical. However, lot-to-lot variability in purity and the presence of the alpha-lapachone isomer as a synthetic impurity are documented, and on-receipt analytical confirmation is appropriate for any investigation where dose-response precision is important. Investigators should specifically verify the absence of alpha-lapachone contamination, as the alpha isomer has distinct biological activity and is a common byproduct of the lapachol cyclization synthesis.

9. Reconstitution and Handling

Beta-lapachone is supplied as a yellow crystalline powder and is poorly soluble in water. For research applications, the compound is dissolved in dimethyl sulfoxide (DMSO) to prepare concentrated stock solutions (typically 10 to 50 mM, corresponding to approximately 2.4 to 12 mg/mL). DMSO stock solutions should be stored at minus 20 degrees Celsius and are stable for at least 6 months when protected from light and moisture. Working dilutions for cell culture experiments are prepared by dilution of DMSO stocks into culture medium; the final DMSO concentration should be maintained at or below 0.1 percent (v/v) to avoid solvent toxicity.

For in vivo studies, beta-lapachone is typically formulated in HPbeta-CD (40 percent w/v in phosphate-buffered saline or sterile water) to achieve adequate solubilization for intravenous or intraperitoneal administration. The HPbeta-CD inclusion complex is prepared by adding beta-lapachone to the cyclodextrin solution with stirring at 50 to 60 degrees Celsius until a clear yellow solution is obtained, followed by sterile filtration through a 0.22-micrometer membrane [4]. The complexed solution is stable at refrigerated conditions (2 to 8 degrees Celsius) for at least 7 days.

Alternative formulation approaches for in vivo administration include polymeric micelle encapsulation (poly(ethylene glycol)-block-poly(D,L-lactic acid) micelles) and liposomal formulations, which provide improved tumor accumulation through enhanced permeability and retention [27].

Light protection is recommended during handling and storage, as naphthoquinones are susceptible to photodegradation. The compound should be handled in a chemical fume hood with standard personal protective equipment (gloves, laboratory coat, safety glasses). Beta-lapachone is classified as an irritant; avoid inhalation of dust and contact with skin and eyes.

10. Stack Interaction Considerations

Investigators conducting research with beta-lapachone, particularly in combination studies or in vivo experiments with concurrent drug administration, should consider:

NQO1 inhibitors: Dicoumarol and other NQO1 inhibitors (ES936, 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione) completely abrogate beta-lapachone cytotoxicity and should not be co-administered unless the intent is to confirm NQO1 dependence as a mechanistic control. Warfarin and coumarin anticoagulants have structural similarity to dicoumarol but are weak NQO1 inhibitors at therapeutic concentrations.

PARP inhibitors: Olaparib, talazoparib, niraparib, rucaparib, and veliparib produce synergistic cytotoxicity when combined with beta-lapachone in NQO1-positive cancer cells. The synergy is based on PARP inhibitor trapping of PARP1 at beta-lapachone-induced DNA damage sites, converting repairable single-strand breaks into lethal double-strand breaks [13]. This combination is under active preclinical investigation and represents a rational therapeutic strategy.

Catalase and antioxidants: Exogenous catalase completely abrogates beta-lapachone cytotoxicity by scavenging the hydrogen peroxide intermediate [8]. N-acetyl cysteine and other thiol antioxidants partially attenuate cytotoxicity. Investigators should avoid concurrent administration of high-dose antioxidant supplements in beta-lapachone efficacy studies.

DNA repair modulators: Inhibitors of base excision repair (methoxyamine, an APE1 inhibitor) synergize with beta-lapachone by preventing repair of oxidative DNA lesions [14]. PCNA inhibitors similarly enhance cytotoxicity [29].

Ionizing radiation: Beta-lapachone enhances radiation sensitivity in NQO1-positive cancer cells through additive DNA damage and NQO1-dependent radiosensitization [14]. The combination is under preclinical investigation for NQO1-positive non-small cell lung cancer and pancreatic cancer.

Gemcitabine and other nucleoside analogs: The combination of beta-lapachone with gemcitabine is the principal clinical combination studied. Beta-lapachone-mediated NAD⁺ depletion and metabolic disruption may synergize with gemcitabine-mediated inhibition of ribonucleotide reductase and DNA synthesis [23].

CYP3A4 inhibitors and inducers: Beta-lapachone is metabolized in part by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase beta-lapachone exposure. Strong inducers (rifampin, carbamazepine, phenytoin) may reduce exposure. The clinical significance of CYP3A4 interactions has not been formally characterized in human pharmacokinetic studies.

Agents causing methemoglobinemia: Concurrent use with dapsone, nitrites, local anesthetics (benzocaine, prilocaine), or other agents known to induce methemoglobinemia may produce additive risk, given that methemoglobinemia is a dose-limiting toxicity of beta-lapachone in clinical settings [12].

11. Adverse Events and Safety

11.1 Dose-limiting toxicities

The principal dose-limiting toxicities in clinical trials of ARQ 761 are:

- Hemolytic anemia (grade 2 to 3; observed in up to 79 percent of patients at the maximum tolerated dose, reflecting off-target redox cycling of beta-lapachone with erythrocyte cytochrome b5 reductase 1)
- Methemoglobinemia (grade 2 to 3; observed as transient hypoxia in 26 to 33 percent of patients, self-resolving within hours of infusion completion)

These toxicities are attributable to the quinone pharmacophore interacting with erythrocyte reductases in an NQO1-independent manner and represent the principal therapeutic-index limitation of the compound [12].

11.2 Common adverse events

At tolerable doses in the Phase I ARQ 761 trial:

- Anemia (79 percent; grade 1 to 3; dose-dependent)
- Fatigue (45 percent; grade 1 to 2)
- Hypoxia (33 percent; grade 1 to 3; reflecting methemoglobinemia)
- Nausea (17 percent; grade 1 to 2)
- Vomiting (17 percent; grade 1 to 2)

11.3 Vehicle-related toxicity

The HPbeta-CD vehicle used in the ARQ 501 formulation contributed to hemolytic toxicity at the high concentrations required for drug solubilization. This vehicle-related hemolysis was a principal factor motivating reformulation to ARQ 761. Investigators using HPbeta-CD for in vivo formulation of beta-lapachone should include vehicle-only control groups and should monitor for hemolysis at cyclodextrin concentrations above 20 percent (w/v) [11].

11.4 NQO1 polymorphism and safety

NQO1*2/*2 homozygous individuals (approximately 4 percent of European-ancestry populations, approximately 22 percent of East Asian populations) lack functional NQO1 protein. Tumors in these individuals are resistant to beta-lapachone, and NQO1 genotyping is a rational companion diagnostic for patient selection. The safety implications of NQO1 polymorphism relate principally to efficacy (lack of antitumor activity) rather than to adverse events, as the cytotoxic mechanism is NQO1-dependent while the hemolytic toxicity is NQO1-independent.

11.5 Preclinical safety

In rodent preclinical toxicology, the principal findings are hemolytic anemia at high doses (consistent with the clinical toxicity profile) and hepatic enzyme elevation at supratherapeutic doses. No genotoxicity signal has been reported in standard in vitro genotoxicity assays (Ames test, chromosomal aberration assay), consistent with the mechanism of action (oxidative DNA damage is confined to cells with high NQO1 activity). Reproductive toxicity data are limited; the compound has not been evaluated in formal reproductive toxicology studies.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five NQO1-targeted or naphthoquinone-class compounds against beta-lapachone, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five candidates were selected as compounds with mechanistic relevance to the NQO1-bioactivatable or naphthoquinone pharmacology space.

12.1 Deoxynyboquinone (DNQ)

Mechanism: NQO1-bioactivatable quinone. DNQ undergoes NQO1-mediated futile redox cycling analogous to beta-lapachone but is approximately 10-fold more potent, with IC₅₀ values of approximately 0.1 to 0.5 micromolar in NQO1-positive cancer cells [30]. The enhanced potency is attributed to a faster rate of hydroquinone autoxidation and a higher superoxide generation rate per redox cycle.

Development trajectory: DNQ was developed as a second-generation NQO1-bioactivatable drug at the University of Illinois at Urbana-Champaign (Bhatt, Borch, and Bhowmik laboratories). The compound has been characterized in NQO1-positive pancreatic and lung cancer cell lines and in xenograft models. It has not entered clinical development. Research-grade DNQ is available from specialty chemical suppliers.

Novelty: Moderate. The NQO1-bioactivation mechanism is shared with beta-lapachone; the chemical scaffold (acetoxo-substituted naphthoquinone) is distinct.

Effect size: Superior to beta-lapachone in vitro on a molar potency basis (approximately 10-fold lower IC₅₀). In vivo efficacy data are limited to preclinical xenograft models.

Promising potential: Low to moderate. The compound has not entered clinical trials and lacks the extensive preclinical and clinical dataset of beta-lapachone. Its principal value is as a more potent research tool for NQO1-dependent pharmacology.

Side-effect profile: Preclinical only. Expected to share the hemolytic anemia and methemoglobinemia liabilities of beta-lapachone based on the shared quinone pharmacophore.

Overall validation: Low. No clinical data. Limited in vivo preclinical data.

Comparison to beta-lapachone: DNQ is more potent than beta-lapachone at the cellular level but lacks the clinical and extensive preclinical validation. Beta-lapachone has the advantages of clinical trial experience, established formulation strategies, and a substantially larger research literature.

12.2 Lapachol

Mechanism: Prenylated 1,4-naphthoquinone, the natural product precursor to beta-lapachone. Lapachol is a modest NQO1 substrate but does not undergo efficient futile redox cycling. Its principal anticancer mechanism is vitamin K antagonism and inhibition of electron transport chain complex II. Lapachol also exhibits antimicrobial and anti-inflammatory activities [1, 20].

Development trajectory: Lapachol entered NCI-sponsored Phase I clinical trials for cancer in the early 1970s but was discontinued due to vitamin K antagonism producing clinically significant anticoagulation at therapeutic doses [20]. The compound is not in active clinical development for any indication.

Novelty: Low. The compound is a well-characterized natural product with a 140-year research history.

Effect size: Modest as an anticancer agent. Insufficient therapeutic index for clinical development owing to the anticoagulant toxicity at effective antitumor doses.

Promising potential: Low. Clinical development terminated in the 1970s. The compound serves as the synthetic precursor to beta-lapachone and as a reference naphthoquinone.

Side-effect profile: Vitamin K antagonism producing dose-dependent coagulopathy is the dose-limiting toxicity. Gastrointestinal toxicity (nausea, vomiting) was also observed in Phase I trials.

Overall validation: Low for anticancer application. High as a natural product chemistry reference compound.

Comparison to beta-lapachone: Lapachol is the synthetic precursor but is pharmacologically inferior for anticancer applications. Beta-lapachone lacks the anticoagulant toxicity and has substantially higher NQO1-dependent cytotoxic potency. Lapachol retains value as a starting material for semi-synthesis.

12.3 Dunnione

Mechanism: Naturally occurring 1,2-naphthoquinone from *Streptocarpus dunnii*. Dunnione is an NQO1 substrate that undergoes futile redox cycling analogous to beta-lapachone but with lower catalytic efficiency. The compound has been characterized for NQO1-dependent anti-inflammatory and cytoprotective activities, including protection against cisplatin-induced nephrotoxicity through NQO1-mediated NADH oxidation and AMPK/SIRT1 activation [31].

Development trajectory: Dunnione has not entered clinical development. It is characterized principally in preclinical models of kidney injury, liver injury, and inflammation. Research-grade dunnione is available from specialty suppliers.

Novelty: Moderate. Shares the NQO1-dependent naphthoquinone mechanism with beta-lapachone but is investigated primarily for cytoprotective rather than cytotoxic applications.

Effect size: Modest as an NQO1-dependent cytoprotective agent in preclinical models. Not characterized as an anticancer agent.

Promising potential: Low. No clinical development. Limited preclinical dataset.

Side-effect profile: Preclinical only. Expected to share some of the naphthoquinone-class liabilities.

Overall validation: Low. Small research literature confined to preclinical cytoprotection studies.

Comparison to beta-lapachone: Dunnione and beta-lapachone share the NQO1-dependent mechanism but are positioned for different applications (cytoprotection versus cytotoxicity). Beta-lapachone has a vastly larger research literature, clinical trial experience, and broader characterization.

12.4 Menadione (Vitamin K3)

Mechanism: Unsubstituted 1,4-naphthoquinone (2-methyl-1,4-naphthoquinone). Menadione undergoes one-electron reduction by cytochrome P450 reductase and other flavoenzymes to produce a semiquinone radical that generates superoxide through autoxidation. Unlike beta-lapachone, menadione is a poor NQO1 substrate and undergoes predominantly one-electron rather than two-electron reduction, producing less selective oxidative stress [32]. Menadione also alkylates protein and glutathione thiols through Michael addition.

Development trajectory: Menadione has been investigated as an anticancer agent in combination with ascorbate (vitamin C) and with conventional chemotherapy. Phase I/II trials of the menadione/ascorbate combination (Apatone) were conducted in prostate cancer patients in the 2000s with modest results [33]. The compound is not in active clinical development for oncology.

Novelty: Low. Menadione is a well-characterized synthetic vitamin K analog with a research history spanning more than 80 years.

Effect size: Modest as an anticancer agent. Non-selective oxidative stress mechanism limits the therapeutic index.

Promising potential: Low for oncology. The compound retains pharmacological use as a vitamin K3 supplement in veterinary medicine.

Side-effect profile: Hemolytic anemia (especially in glucose-6-phosphate dehydrogenase-deficient individuals), hepatotoxicity, and oxidative damage to normal tissues. The non-selective oxidative stress mechanism produces a narrower therapeutic index than the NQO1-selective mechanism of beta-lapachone.

Overall validation: Moderate as a research tool for redox biology. Low for anticancer clinical application.

Comparison to beta-lapachone: Menadione shares the naphthoquinone scaffold but lacks NQO1 selectivity, producing non-selective oxidative stress. Beta-lapachone is pharmacologically superior for tumor-selective applications owing to the NQO1-dependent bioactivation mechanism. The comparison illustrates the importance of the NQO1-selective two-electron reduction for the therapeutic index of beta-lapachone.

12.5 IB-DNQ (Isobutyl-deoxynyboquinone)

Mechanism: Structural analog of deoxynyboquinone (DNQ) with enhanced NQO1-dependent cytotoxic potency. IB-DNQ is reported to be approximately 100-fold more potent than beta-lapachone and approximately 10-fold more potent than DNQ in NQO1-positive cancer cell lines, with IC50 values in the low-nanomolar range [34]. The mechanism is the same NQO1-mediated futile redox cycling as beta-lapachone and DNQ, with further optimized autoxidation kinetics.

Development trajectory: IB-DNQ is a research compound developed at the University of Illinois. It has been characterized in vitro and in limited in vivo xenograft models. It has not entered clinical development. Availability is restricted to research collaborations and specialty synthesis.

Novelty: Moderate to high. The optimized NQO1-bioactivatable scaffold represents the most potent NQO1-dependent quinone characterized to date.

Effect size: Very high in vitro potency in NQO1-positive cells. Limited in vivo data.

Promising potential: Low. No clinical development. No formulation development. Limited availability.

Side-effect profile: Unknown. Expected to share naphthoquinone-class hemolytic liabilities, potentially exacerbated by the higher potency.

Overall validation: Low. Very small research literature. No clinical or extensive preclinical data.

Comparison to beta-lapachone: IB-DNQ represents the current potency frontier for NQO1-bioactivatable drugs but lacks all of the translational infrastructure (formulation, pharmacokinetics, clinical trial experience, safety database) that beta-lapachone has accumulated. Beta-lapachone remains the reference compound for the NQO1-bioactivatable class and the only member to have reached clinical trials.

12.6 Comparator summary

The five compounds occupy distinct positions relative to beta-lapachone in the NQO1-bioactivatable and naphthoquinone pharmacology space. **Deoxynyboquinone (DNQ)** and **IB-DNQ** represent more potent NQO1-bioactivatable alternatives with no clinical validation. **Lapachol** is the natural product precursor

with inferior pharmacology (anticoagulant toxicity, poor NQO1 cycling) and terminated clinical development. **Dunnione** shares the NQO1 mechanism but is positioned for cytoprotection rather than cytotoxicity. **Menadione** illustrates the pharmacological liability of non-selective naphthoquinone redox cycling compared to the NQO1-selective mechanism of beta-lapachone.

Beta-lapachone occupies a unique position as the only NQO1-bioactivatable compound to have reached clinical trials, the compound with the most extensive pre-clinical characterization across oncology, metabolic, and inflammatory indications, and the reference substrate for NQO1-dependent pharmacology. Its principal limitation is the hemolytic anemia and methemoglobinemia caused by off-target erythrocyte redox cycling, which narrows the therapeutic index and has prevented single-agent registration. Current research focuses on rational combination strategies (with PARP inhibitors, radiation, and DNA repair inhibitors) that exploit the NQO1-selective DNA damage mechanism at tolerable doses, and on improved delivery systems (polymeric micelles, nanoparticles) that increase tumor drug exposure while reducing systemic erythrocyte exposure.

13. References

1. Hussain H, Green IR. Lapachol and lapachone analogs: a journey of two decades of patent research (1997-2016). *Expert Opin Ther Pat*. 2017;27(10):1111-1121.
2. de Almeida ER. Preclinical and clinical studies of lapachol and beta-lapachone. *Open Nat Prod J*. 2009;2:42-47.
3. Nasongkla N, Wiedmann AF, Bruber A, et al. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. *Pharm Res*. 2003;20(10):1626-1633.
4. Blanco E, Bey EA, Khemtong C, et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. *Cancer Res*. 2010;70(10):3896-3904.
5. Eyong KO, Kumar PS, Kuete V, Folefoc GN, Nkengfack EA, Baskaran S. Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol. *Bioorg Med Chem Lett*. 2008;18(20):5387-5390.
6. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. *J Biol Chem*. 2000;275(8):5416-5424.
7. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. *Proc Natl Acad Sci USA*. 2007;104(28):11832-11837.
8. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. *J Biol Chem*. 2006;281(44):33684-33696.
9. Huang X, Dong Y, Bey EA, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1 hyperactivation. *Cancer Res*. 2012;72(12):3038-3047.
10. Yang Y, Zhang Y, Wu Q, et al. Clinical implications of high NQO1 expression in breast cancers. *J Exp Clin Cancer Res*. 2014;33:14.

11. ArQule, Inc. Phase I trial of ARQ 501, an activated checkpoint therapy agent, in patients with advanced solid tumors. *J Clin Oncol*. 2005;23(16_suppl):3042.
12. Gerber DE, Beg MS, Fattah F, et al. Phase 1 study of ARQ 761, a beta-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. *Br J Cancer*. 2018;119(8):928-936.
13. Huang X, Motea EA, Moore ZR, et al. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase inhibitors. *Cancer Cell*. 2016;30(6):900-916.
14. Dong Y, Bey EA, Li LS, et al. Proton pump inhibitors alter specific tumor suppressor pathways in NQO1 bioactivatable drug-treated non-small cell lung cancers. *J Biol Chem*. 2010;285(51):40209-40216.
15. Kim YH, Hwang JH, Noh JR, et al. Beta-lapachone prevents diet-induced obesity by increasing energy expenditure and stimulating the browning of white adipose tissue via downregulation of miR-382 expression. *Diabetes*. 2016;65(9):2490-2501.
16. Lee EJ, Ko HM, Jeong YH, Park EM, Kim HS. Beta-lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. *J Neuroinflammation*. 2015;12:133.
17. Salas CO, Faundez M, Morello A, Maya JD, Tapia RA. Natural and synthetic naphthoquinones active against *Trypanosoma cruzi*: an initial step towards new drugs for Chagas disease. *Curr Med Chem*. 2011;18(1):144-161.
18. Oh GS, Kim HJ, Choi JH, et al. Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials. *Drug Des Devel Ther*. 2017;11:3187-3195.
19. Gomes de Melo J, de Sousa Santos RA, de Amorim ELC, do Nascimento SC, de Albuquerque UP. Medicinal plants used as antitumor agents in Brazil: an ethnobotanical approach. *Evid Based Complement Alternat Med*. 2011;2011:365359.
20. Block JB, Serpick AA, Miller W, Wiernik PH. Early clinical studies with lapachol (NSC-11905). *Cancer Chemother Rep Part 2*. 1974;4(4):27-28.

21. Li LS, Bey EA, Dong Y, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. *Clin Cancer Res.* 2011;17(2):275-285.
22. Hartner LP, Rosen L, Hensley M, et al. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. *J Clin Oncol.* 2007;25(18_suppl):15096.
23. Cullen JJ. A phase I/Ib, multi-center trial of ARQ-761 (beta-lapachone) with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer. *Ann Oncol.* 2019;30(Suppl 4):iv126.
24. Li CJ, Averboukh L, Bhagat S, Bhagat L, Pardee AB. Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. *J Biol Chem.* 1993;268(30):22463-22468.
25. Savage RE, Tyler AN, Miao XS, Chan TC. Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals. *Drug Metab Dispos.* 2008;36(4):753-758.
26. Kim DH, Lee SE, Pyo YC, Tran P, Park JS. Oral bioavailability enhancement of beta-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion. *Int J Pharm.* 2018;539(1-2):124-131.
27. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. *Cancer Sci.* 2011;102(7):1247-1252.
28. Kang HE, Jung HY, Cho YK, et al. The possibility of low isomerization of beta-lapachone in the human body. *Transl Clin Pharmacol.* 2021;29(3):e16.
29. Srivastava IK, Morrissey JM, Darrouzet E, Daldal F, Vaidya AB. PCNA inhibition enhances the cytotoxicity of beta-lapachone in NQO1-positive cancer cells by augmentation of oxidative stress-induced DNA damage. *Cancer Lett.* 2021;519:210-222.
30. Parkinson EI, Bair JS, Cismesia MA, Hergenrother PJ. Efficient NQO1 substrates are potent and selective anticancer agents. *ACS Chem Biol.* 2013;8(10):2173-2183.

31. Gang GT, Kim YH, Noh JR, et al. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity. *Toxicol Lett.* 2013;221(3):165-175.
 32. Criddle DN, Gillies S, Baumgartner-Wilson HK, et al. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. *J Biol Chem.* 2006;281(52):40485-40492.
 33. Tareen B, Summers JL, Jamison JM, et al. A 12-week, open-label, Phase I/IIa study using Apatone for the treatment of prostate cancer patients who have failed standard therapy. *Int J Med Sci.* 2008;5(2):62-67.
 34. Parkinson EI, Hergenrother PJ. Deoxynyboquinones as NQO1-activated cancer therapeutics. *Acc Chem Res.* 2015;48(10):2715-2723.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Beta-lapachone is not approved by any regulatory authority for any therapeutic indication. The compound is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.